# Nura Bio

**Canonical:** https://apis.io/providers/nura-bio/  
**Website:** https://nurabio.com/  
**APIs profiled:** 2

Nura Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing neuroprotective small-molecule medicines that halt neurodegeneration before it progresses. Conceived in 2018 by The Column Group together with scientific founders Steve McKnight, PhD and Marc Freeman, PhD, the company targets SARM1 — a neuronally enriched NAD hydrolase that acts as an axon-intrinsic metabolic sensor and central driver of axonal degeneration — on the thesis that intervening early in that pathway confers durable structural and functional neuroprotection across peripheral, central and ocular nervous-system disorders. Its pipeline is led by NB-4746, a first-generation oral, brain-penetrant, reversible orthosteric SARM1 inhibitor in a global Phase 1b/2a study in ALS, and NB-9402, a mechanistically differentiated second-generation oral, covalent, irreversible, allosteric inhibitor completing a Phase 1a healthy-volunteer study in 2026. Nura Bio launched publicly in January 2020 with a $73 million Series A, extended that round with $68 million to pass $140 million raised, and closed a $73.8 million Series B in June 2026 led by The Column Group with Euclidean Capital, Samsara BioCapital and Sanofi Ventures; Shilpa Sambashivan, PhD, a co-founder and its chief scientist, serves as CEO. Its science is published in NEURON and CELL REPORTS. Nura Bio runs no developer program and publishes no product API, developer portal, API reference, SDK or pricing. The only machine-readable surfaces reachable without credentials are a published llms.txt and the WordPress REST content API behind nurabio.com, which serves the news archive, site pages, people directory and media library as JSON — both catalogued here.

## Kin Score — 27.0 / 100 (thin)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 27.0).

| Facet | Score |
|---|---|
| Discoverability | 75.9 |
| Contract Quality | 52.4 |
| Governance | 4.5 |
| Contract Governance | 4.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 13.7 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 38.8 (matched via tags).

## Agent readiness — 21.8 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | bearer |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Self-serve signup — onboarding: self-serve, pricing: unknown, trial: no (confidence: medium).

## APIs (7)

- **Nura Bio Directory API** — Public author projection for users who have published content.
- **Nura Bio Discovery API** — Route, type, taxonomy, status and oEmbed discovery endpoints that describe the deployment itself.
- **Nura Bio Media API** — The media library: logo assets, team headshots, scientific figures and press-release documents.
- **Nura Bio Pages API** — The six evergreen site pages: Home, About Us, Our Science, News & Literature, Join Us, Contact.
- **Nura Bio Portfolio API** — The people directory — leadership, board of directors, and founders and advisors — carried on the Avada theme `portfolio` custom post type and its `portfolio_entries` taxonomy.
- **Nura Bio Posts API** — The company news archive — press releases and financing, clinical and publication announcements.
- **Nura Bio Taxonomy API** — Category and tag terms applied to the news archive.

## Security (2)

- **Nura Bio Authentication** — 2 schemes
- **Nura Bio Domain Security** — TLSv1.3 · DMARC

## Plans (1)

- **Nura Bio Plans Pricing**

## Tags

Company, Biotechnology, Pharmaceuticals, Neuroscience, Neurodegeneration, Drug Discovery, Life Sciences, Clinical Trials, Rare Disease, Small Molecule Therapeutics, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/nura-bio/). Scores are computed from the provider's own public artifacts under a published rubric.